Plain-English translation of NCT06475417 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new approach to treating locally advanced stomach cancer. Patients will receive adebrelimab (an immunotherapy drug) combined with three chemotherapy medicines before having surgery to remove the cancer. Researchers want to see if this pre-surgery treatment helps shrink tumors and makes surgery more successful.
Currently, patients with advanced stomach cancer often receive chemotherapy after surgery. This trial is exploring whether giving this medication before surgery instead—when combined with three chemotherapy drugs—could be more effective and help doctors remove the cancer more completely.
If you join this trial, you will receive three cycles of the combination treatment (the new drug plus chemotherapy) before surgery, with each cycle lasting about three weeks. Three to six weeks after finishing the medication, you'll have imaging scans to see how well the treatment worked. Then you'll have surgery to remove the cancer. The study involves regular clinic visits for treatment, blood tests, and imaging exams to monitor your progress and safety.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Tang-Du Hospital
Collaborators
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Enrollment target
~42 participants
Started
May 2024
Primary completion
May 2025
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nan Wang, Dr
Tang-Du Hospital